MEDBOX Issue Brief no.30. In diesem Issue Brief finden Sie wichtige Hintergrundsmaterialien, Dokumente zu Fragen rund um klinische Aspekte, Aufklärungsmaterialien und Materialien zum internationalen Kontext.
doi: https://doi.org/10.1101/2020.10.28.20221143
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
- The goal of diagnostic testing for Ebola and Marburg virus diseases is to identify cases to provide timely and appropriate care and to stop disease transmission.
- All individuals meeting the case definition for Ebola or Marburg virus diseases should be tested.
- The recommended sample type ...for testing for orthoebolaviruses and orthomarburgviruses is whole blood or plasma for living patients, and oral swab for deceased individuals.
- Laboratory confirmation of Orthoebolavirus and Orthomarburgvirus infections and further species identification should be done using nucleic acid amplification testing (NAAT).
- If a suspected case tests negative (living patient) and the blood was drawn less than 72 hours after symptom onset, a second test should be performed with blood drawn more than 72 hours after symptom onset.
- All manipulations in laboratory settings of samples originating from suspected, probable or confirmed cases of Ebola and Marburg virus diseases should be conducted with appropriate biosafety measures according to a risk-based approach.
- Whole or partial genome sequencing can be used to characterize viruses and complement epidemiologic investigations.
- Member States are strongly encouraged to share genetic sequence data (GSD) in publicly accessible databases.
- Member States are required to immediately notify the World Health Organization (WHO) under the International Health Regulations (IHR) 2005 of positive laboratory results.
more
Рекомендации ВОЗ по оказанию дородовой помощи для формирования положительного опыта беременности
The Zimbabwe National Pharmacovigilance Policy Handbook, 2nd Edition updates the November 2013 version to indicate the Zimbabwe National Pharmacovigilance (PV) Centre’s compliance with the WHO Pharmacovigilance Indicators Handbook 2015.
Health and Human Rights Journal
December 2016 / Volume 18 / Number 2 / Papers, 171-182
Regional Tuberculosis Program, Pan American Health Organization (PAHO/WHO)
20 February 2013
Update on 2004 Background Paper (Written by Saloni Tanna)
Priority Medicines for Europe and the World "A Public Health Approach to Innovation"
Other disorders
Chapter H.6
SADC Communicable Disease Project
Component 5: Scaling-up Child and Adolescent HIV, TB and Malaria Continuum of Care and Support
DRAFT POST REGIONAL CONSENSUS AND VALIDATION MEETING Oct 2012
Frontiers in Public Health | www.frontiersin.org 1 June 2017 | Volume 5 | Article 127
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection
Accessed: 26.02.2020